SCHEDULE: Apeiron Boosts Stake in ATAI Life Sciences to 24.3%

Apeiron Investment Group and affiliates increased their beneficial ownership in ATAI Life Sciences N.V. to 24.3% through a $19 million PIPE financing.

Summary

• Apeiron Investment Group Ltd. and its affiliates, including Apeiron Presight Capital Fund II, L.P., Presight Capital Management I, L.L.C., Fabian Hansen, and Christian Angermayer, collectively increased their beneficial ownership in ATAI Life Sciences N.V.
• As of August 14, 2025, the reporting persons collectively beneficially own 55,197,516 Ordinary Shares, representing approximately 23.7% of the voting rights.
• Christian Angermayer's total beneficial ownership, including vested options, amounts to 56,501,513 Ordinary Shares, representing 24.3% of the class.
• Apeiron purchased 8,675,799 Ordinary Shares in a Private Investment in Public Equity (PIPE) financing for approximately $19,000,000.
• The funds for Apeiron's purchase were drawn from a facility agreement with Joh. Berenberg, Gosser & Co. KG, dated August 14, 2025.
• The total outstanding Ordinary Shares as of August 14, 2025, including shares issued in the PIPE Financing, are 232,602,562.
• The reporting persons also hold 2,367,200 Ordinary Shares underlying convertible promissory notes and 1,303,997 vested options exercisable at $5.68 per share.

Sentiment

Score: 7

Explanation: The filing indicates a significant investment by a major shareholder, increasing their stake and demonstrating strong confidence in the company. This capital infusion is generally positive for the company's financial stability and future prospects. While the investor used debt, this is a common financing mechanism and doesn't detract from the positive signal of the investment itself.

Positives

• A significant investment of approximately $19 million by Apeiron Investment Group demonstrates strong confidence from a major shareholder in ATAI Life Sciences N.V.'s future.
• The increased beneficial ownership by key investors, including Christian Angermayer, to 24.3% signals a deeper commitment and alignment with the company's long-term strategy.
• The PIPE financing provides capital to ATAI Life Sciences N.V., which can be used for operational needs, research and development, or other strategic initiatives.

Negatives

• The financing involved drawing proceeds under a facility agreement, indicating the use of debt to fund the share purchase, which could imply leverage for the investor.

Future Outlook

The Issuer is required to file a registration statement under the Securities Act of 1933 for the resale of shares held by PIPE Investors and use reasonable best efforts to cause it to be declared effective within specified timelines, and thereafter keep it effective.

Industry Context

This filing indicates a significant capital infusion and increased insider ownership in ATAI Life Sciences, a company operating in the biotechnology sector, specifically focusing on psychedelic-based therapies. Such investments are common in the capital-intensive biotech industry, where companies often rely on private placements to fund research and development, especially for novel therapeutic approaches.

Comparison to Industry Standards

• The PIPE financing structure is a standard method for biotech companies to raise capital from institutional or strategic investors, similar to recent private placements seen with companies like Compass Pathways (CMPS) or MindMed (MNMD) in the psychedelic therapeutics space, though specific deal terms vary.
• An investor group increasing its stake to over 20% is a strong signal of conviction, comparable to significant strategic investments observed in other emerging biotech firms where early investors deepen their commitment as clinical programs advance.
• The inclusion of a Registration Rights Agreement is standard practice in PIPE deals, ensuring liquidity for the investors' shares post-investment, aligning with typical agreements in similar private placements across the biotech and pharmaceutical sectors.

Related Party Transactions

• Apeiron Investment Group Ltd. and Christian Angermayer are related parties to ATAI Life Sciences N.V. through their significant ownership and influence.
• The PIPE Financing involved Apeiron purchasing shares from the Issuer.
• The HSR Filing Letter Agreement involves the Issuer reimbursing Apeiron for certain expenses.

Stakeholder Impact

• Shareholders: The increased stake by a major investor could be seen as a vote of confidence, potentially stabilizing or boosting investor sentiment. The PIPE financing dilutes existing shareholders to some extent but provides capital for the company.
• Creditors: The company's financial position may be strengthened by the capital raise, potentially improving its ability to meet obligations.
• Employees: A stronger financial position could support ongoing operations and future growth, benefiting employees through job security and potential expansion.

Next Steps

• ATAI Life Sciences N.V. is required to file a registration statement under the Securities Act of 1933 for the resale of shares held by the PIPE Investors.
• The Issuer must use reasonable best efforts to cause the registration statement to be declared effective within specified timelines and keep it effective for the required periods.

Key Dates

Recommendation

The filing indicates a significant vote of confidence from a major existing investor through a substantial PIPE financing, which is generally positive for the company's capital structure and strategic initiatives. However, as a Schedule 13D amendment, it primarily reports a completed transaction and updated ownership, rather than new operational or financial performance data. While the increased insider ownership is a bullish signal, without additional information on the company's recent operational performance, clinical trial progress, or market conditions, a 'hold' recommendation is prudent. This allows investors to acknowledge the positive insider commitment while awaiting further fundamental updates that could justify a stronger 'buy' or 'sell' position.

Keywords

ATAI Life Sciences, Apeiron Investment Group, Christian Angermayer, PIPE financing, Schedule 13D, beneficial ownership, equity investment, biotechnology, pharmaceuticals, psychedelics